Commodore Capital LP Has $69.67 Million Stock Position in Celldex Therapeutics, Inc. $CLDX

Commodore Capital LP lessened its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 15.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,565,000 shares of the biopharmaceutical company’s stock after selling 463,335 shares during the quarter. Celldex Therapeutics accounts for about 4.6% of Commodore Capital LP’s investment portfolio, making the stock its 8th largest position. Commodore Capital LP owned 3.86% of Celldex Therapeutics worth $69,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd bought a new position in Celldex Therapeutics in the 3rd quarter valued at $26,000. Wilmington Savings Fund Society FSB bought a new position in Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Quantbot Technologies LP bought a new position in Celldex Therapeutics in the 3rd quarter valued at $63,000. Finally, Kestra Advisory Services LLC bought a new position in Celldex Therapeutics in the 4th quarter valued at $98,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CLDX. Barclays lifted their price objective on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group lifted their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a research report on Monday. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a research report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $49.30.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $32.93 on Thursday. The stock has a fifty day moving average of $31.96 and a 200-day moving average of $28.97. The stock has a market capitalization of $2.58 billion, a P/E ratio of -7.73 and a beta of 0.95. Celldex Therapeutics, Inc. has a 52 week low of $19.52 and a 52 week high of $35.79.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts forecast that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.